Business
AbbVie bets $10.9 billion on Apogee in growth push
RTÉAbbVie said today it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline.
RTÉAbbVie said today it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline.